• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 5/30/24: Strategies for Conducting Strong, Efficient Peer Reviews of Papers, Smart Bandages Are on the Way & more


The latest news for pharma industry insiders.

AI in Clinical Trials: A Long, But Promising Road Ahead

Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.

Strategies for Conducting Strong, Efficient Peer Reviews of Papers

A methodical approach can optimize the evaluation of a paper.

Smart Bandages That Heal Wounds Faster and Talk to Your Doctor Are on the Way

Researchers are working on bandages that allow remote monitoring and deliver treatment with zaps of light or electricity.

Merck to Acquire EyeBio

Merck, known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

EntityRisk on LinkedIn:

Pharmaceutical Executive cited Darius Lakdawalla in its coverage of the Financial Times US Pharma and Biotech Summit 2024.

“It'll take probably five or 10 years to play out on the negotiation side,” Darius said, “which is really more price setting than it is negotiation. There is a lot of question about what CMS is going to do to set prices. And they've been pretty vague about how they're going to do that in order to preserve flexibility and discretion. In fact, I think it's clear that the guidance that they issued for this year's price saying they're not going to hold themselves to in future years. So even if you look at if you look at what happens in the fall, you're not going to get a lot of insight into what's going to happen in the following years. So that's part of the uncertainty. Then there's also a market level uncertainty, which is because of the inflation boundaries that, in some ways, probably pose the most pivotal risk for the industry. The question is, how is that going to be handled? So now there's asymmetric risk when you set your launch prices. If you set your launch price too low, there's not really a way out.”

The PROVEN Platform is where Darius and the team have been working out how the value of medicine is being understood and misunderstood through these changes. Please let us know if you would like to see PROVEN yourself.

Read the full article here: https://lnkd.in/gh67kFbu

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs